Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24201255 | 0.97 | EPHX2 (0.60) | ALDH1A1EPHX2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL19509240 | 0.85 | EPHX2 (0.62) | ALDH1A1EPHX2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL17457691 | 0.84 | ALDH1A1 (0.61) | ALDH1A1EPHX2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL24201247 | 0.82 | EPHX2 (0.62) | ALDH1A1EPHX2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL15532610 | 0.82 | EPHX2 (0.59) | ALDH1A1EPHX2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL24201340 | 0.82 | EPHX2 (0.62) | ALDH1A1EPHX2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL19500375 | 0.81 | EPHX2 (0.58) | ALDH1A1EPHX2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL17471623 | 0.81 | EPHX2 (0.61) | ALDH1A1EPHX2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL15597241 | 0.81 | EPHX2 (0.61) | ALDH1A1EPHX2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL22225447 | 0.81 | EPHX2 (0.61) | ALDH1A1EPHX2CYP3A4CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3618833-B1 | TRIPARTITE ANDROGEN RECEPTOR ELIMINATORS, METHODS AND USES THEREOF | SPG THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20160022642-A1 | Compounds Useful for Promoting Protein Degradation and Methods Using Same | YALE UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| US-20160022642-A1 | Compounds Useful for Promoting Protein Degradation and Methods Using Same | YALE UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022642-A1 | Compounds Useful for Promoting Protein Degradation and Methods Using Same | AR, SHBG, PSMG3 | ALDH1A1 1243/4885EPHX2 4102/4885CYP3A4 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.